pdufa date for tirzepatide Fresh from the biotech pipeline: too much, too fast? 4 Important Approvals Expected This

Meal replacements followed by topiramate for the treatment of adolescent severe obesity: a pilot randomized controlled trial

The potential role of GLP-1 agonists in treating alcohol use disorder (AUD) has emerged from both animal studies and early-phase human trials, though it is important to emphasise that there is no official licence for these medications in AUD treatment in the UK or elsewhere

semaglutide in other populations and that treatment with semaglutide was well tolerated in healthy Chinese subjects

Participants taking semaglutide 2.4 mg lost an average of 14.9% of body weight

Your genetics may play a role in how you respond to GLP-1 medications